ALDXAldeyra The
This is the year Aldeyra has to prove it’s not just a micro-cap biotech with a high-beta story but a company that can deliver. The next catalyst — the Q3 2026 earnings and Reproxalap regulatory update on 2026-11-04 — is the first real test of whether the stock can break out of its current range, with a modeled bull target of $2.45 and a bear fallback of $1.35. The market is watching to see if the FDA gives Reproxalap a clear path forward, which would re-rate the stock toward the higher end of the range, or if regulatory pushback sends it back down to the lower end. Either way, this is the moment when the story either gets real or gets written off.
The Read
Aldeyra Therapeutics (ALDX) has historically experienced median absolute stock moves of about 10%.
The schedule
- Tue3Nov
- Tue8Dec
Anticipated clinical readout for ADX-2191, a key mid-stage pipeline asset that could diversify Aldeyra's clinical risk profile away from its heavy reliance on Reproxalap.
- Sun14Feb
Q4 results will provide crucial 2027 guidance on capital allocation, operating expenses, and the projected timeline before a highly dilutive capital raise becomes necessary.
- Thu6May
The Q1 2027 earnings report will force a hard reality check on Aldeyra's balance sheet, likely acting as a catalyst for either a strategic transaction or a deeply discounted capital raise.
Past
- Thu6Aug
Actual outcome: Bear · $1.52 at outcome
ALDX reported in-line EPS of -0.0572, matching expectations, but the stock fell 4.4% due to the legal overhang update, which intensified market concerns over the securities fraud class action lawsuits. The price action reflected heightened risk aversion as investors reassessed the company's exposure to litigation, overshadowing the neutral earnings report.
Q2 2026 earnings will focus on confirming the manageable cash burn rate outlined in the June strategic update, while the market assesses any lingering overhang from the recent securities fraud class action lawsuits.
- Thu25Jun
Actual outcome: Bull · $2.05 at outcome
Aldeyra's strategic update alleviated immediate dilution fears by providing clarity on its $65 million cash position and ongoing burn rates. Management outlined a manageable financial runway to support the upcoming Reproxalap trials without an imminent, highly dilutive capital raise, which reassured investors and drove the stock's 13.9% rally.
Market assesses Aldeyra's cash position of $65M against ongoing burn rates and the looming cost of potential new Reproxalap trials, elevating dilution risks.
- Thu7May
Actual outcome: Bear · $1.54 at outcome
Aldeyra Therapeutics reported in-line Q1 earnings with an EPS of -$0.11, but the stock fell 11% following the update. The decline was driven by mounting investor concerns over a wave of securities fraud class action lawsuits alleging that executives omitted inconsistent trial data and made misleading disclosures regarding the company's clinical progress.
Q1 2026 earnings and an update on Reproxalap program milestones at around $1.52 will be watched less for revenue (still near zero) and more for clarity on regulatory interactions and potential partnering, with upside toward $2.10 if management can credibly de-risk the path to NDA resubmission, and downside toward $2.10 if the update again lacks specifics on timelines or cash runway.
- Fri27Feb
Actual outcome: Bear · $4.65 at outcome
Aldeyra met EPS estimates at -$0.11, but the stock fell nearly 15% to hit the bear floor as the update failed to provide positive news regarding the Reproxalap FDA Type A meeting request. The lack of a significant extension to the company's cash runway, a primary focus for investors, drove the sell-off despite the in-line earnings result.
Reporting of Q4 2025 financial results. Investor focus will be on the company's cash burn rate, updated cash runway guidance, and any non-material updates regarding the Reproxalap Type A meeting request with the FDA. A longer-than-expected cash runway is a moderate bullish signal.
